➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Medtronic
McKesson
Colorcon
Dow

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203108


Email this page to a colleague

« Back to Dashboard

NDA 203108 describes STRIVERDI RESPIMAT, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the STRIVERDI RESPIMAT profile page.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride profile page.
Summary for 203108
Tradename:STRIVERDI RESPIMAT
Applicant:Boehringer Ingelheim
Ingredient:olodaterol hydrochloride
Patents:14
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 203108
Generic Entry Date for 203108*:
Constraining patent/regulatory exclusivity:
Dosage:
SPRAY, METERED;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 203108
Mechanism of ActionAdrenergic beta2-Agonists
Suppliers and Packaging for NDA: 203108
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0192 0597-0192-61 1 CARTRIDGE in 1 CARTON (0597-0192-61) > 60 SPRAY, METERED in 1 CARTRIDGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;INHALATIONStrengthEQ 0.0025MG BASE/INH
Approval Date:Jul 31, 2014TE:RLD:Yes
Patent:⤷  Free Forever TrialPatent Expiration:Dec 7, 2023Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Free Forever TrialPatent Expiration:May 12, 2025Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Patent:⤷  Free Forever TrialPatent Expiration:Aug 26, 2024Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 203108

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Boehringer Ingelheim
Colorcon
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.